Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson is a global healthcare company engaged in the research development manufacture and sale of a broad range of products related to human health and well being. The firm operates through subsidiaries that conduct business in virtually every country worldwide. Its core activities include discovering new therapies producing medical devices and delivering products to hospitals clinicians and patients. Johnson & Johnson was incorporated in the State of New Jersey in 1887 and today employs approximately 138 200 people. The company's mission is to improve health outcomes through innovation and responsible business practices.

Revenue is generated primarily from the sale of pharmaceutical products and medical technology devices. The Innovative Medicine segment sells prescription medicines directly to retailers wholesalers distributors hospitals and healthcare professionals. The MedTech segment sells products such as cardiovascular devices orthopaedic implants surgical instruments and vision care items to wholesalers hospitals retailers and eye care professionals. Key contributors to total sales include DARZALEX STELARA TREMFYA XARELTO and the ACUVUE contact lens line. Additional revenue comes from licensing agreements royalties and collaborative development arrangements with external partners.

The company operates through the following segments: Innovative Medicine and MedTech.

• The Innovative Medicine segment focuses on therapeutic areas including oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism. Key products in this segment include CARVYKTI (ciltabtagene autoleucel) a CAR T cell therapy for relapsed refractory multiple myeloma DARZALEX (daratumumab) a treatment for multiple myeloma DARZALEX FASPRO (daratumumab and hyaluronidase fihj) a treatment for multiple myeloma and light chain AL amyloidosis ERLEADA (apalutamide) a next generation androgen receptor inhibitor for the treatment of patients with prostate cancer IMBRUVICA (ibrutinib) a treatment for certain B cell malignancies or blood cancers and chronic graft versus host disease RYBREVANT (amivantamab) a fully human bispecific antibody for adults with EGFR mutated non small cell lung cancer and LAZCLUZE (lazertinib) an oral brain penetrant EGFR tyrosine kinase inhibitor for non small cell lung cancer RYBREVANT FASPRO (amivantamab and hyaluronidase lpuj) a subcutaneous therapy for patients with non small cell lung cancer TALVEY (talquetamab tgvs) a bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy TECVAYLI (teclistamab cqyv) a bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy ZYTIGA (abiraterone acetate) a treatment for patients with prostate cancer REMICADE (infliximab) a treatment for a number of immune mediated inflammatory diseases SIMPONI (golimumab) a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis and moderately active to severely active ulcerative colitis SIMPONI ARIA (golimumab) an intravenous treatment for adults with moderate to severe rheumatoid arthritis active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis in people two years of age and older STELARA (ustekinumab) a treatment for adults and children with moderate to severe plaque psoriasis for adults with active psoriatic arthritis for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis TREMFYA (guselkumab) a treatment for patients with moderate to severe plaque psoriasis active psoriatic arthritis moderate to severe Crohn’s disease and moderate to severe ulcerative colitis CAPLYTA (lumateperone) used in adults along with an antidepressant to treat major depressive disorder depressive episodes associated with bipolar I or bipolar II disorder or to treat schizophrenia CONCERTA (methylphenidate HCl) extended release tablets CII a treatment for attention deficit hyperactivity disorder INVEGA SUSTENNA/XEPLION (paliperidone palmitate) for the treatment of schizophrenia and schizoaffective disorder in adults INVEGA TRINZA/TREVICTA (paliperidone palmitate) for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months SPRAVATO (Esketamine) a nasal spray used along with an oral antidepressant to treat adults with treatment resistant depression and depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions EDURANT (rilpivirine) PREZISTA (darunavir) PREZCOBIX/REZOLSTA (darunavir cobicistat) antiretroviral medicines for the treatment of human immunodeficiency virus in combination with other antiretroviral products SYMTUZA (darunavir cobicistat emtricitabine tenofovir alafenamide) a once daily single tablet regimen for the treatment of HIV OPSUMIT (macitentan) OPSYNVI (macitentan tadalafil) as monotherapy or in combination indicated for the long term treatment of pulmonary arterial hypertension UPTRAVI (selexipag) the only approved oral and intravenous selective IP receptor agonist targeting a prostacyclin pathway in PAH XARELTO (rivaroxaban) an oral anticoagulant for the prevention of deep vein thrombosis which may lead to pulmonary embolism in patients undergoing hip or knee replacement surgery to reduce the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease and peripheral artery disease for the treatment and secondary prevention of thromboembolism in pediatric patients and for thromboprophylaxis in pediatric patients following the Fontan procedure. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.

• The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular orthopaedics surgery and vision supporting physicians hospitals eye care professionals and healthcare systems across a wide range of acute and elective procedures. These products are designed to address disease states where procedural intervention plays a central role in treatment and patient outcomes. The Cardiovascular portfolio includes electrophysiology products used to diagnose and treat heart rhythm disorders mechanical circulatory support technologies (Abiomed) used in patients with cardiogenic shock or those undergoing a high risk percutaneous coronary intervention circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease and peripheral artery disease and neurovascular care that treats stroke and other conditions. These offerings are primarily delivered through minimally invasive catheter based approaches and are used by interventional cardiologists electrophysiologists and neurointerventional specialists. The Orthopaedics portfolio includes products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others. The Surgery portfolio includes a range of surgical products and enabling technologies for use across open laparoscopic and robotic surgical procedures. This portfolio includes instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies designed to support procedural consistency and efficiency across multiple surgical specialties. The Surgery portfolio also includes solutions that focus on breast aesthetics and reconstruction (Mentor). These products are used in hospitals and surgical centers worldwide and are supported by ongoing development of surgical techniques and clinical evidence. The Vision portfolio includes contact lenses marketed under the ACUVUE brand TECNIS premium intraocular lenses for cataract surgery and other products used in cataract and refractive procedures. Vision products are used by eye care professionals and ophthalmic surgeons and span both corrective and surgical vision care. These MedTech products are distributed to wholesalers hospitals and retailers and are used predominantly in the professional fields by physicians nurses hospitals eye care professionals and clinics. In October 2025 the Company announced its intention to separate its Orthopaedics business. The Company intends to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.

Johnson & Johnson holds a leading position in the global healthcare sector due to its diversified portfolio and strong brand recognition. In the pharmaceutical arena it competes with companies such as Pfizer Merck Roche and Novartis. In the medical technology space it faces competition from Medtronic Abbott Boston Scientific and Stryker. The company's competitive advantages include its extensive research and development pipeline its broad distribution network and its ability to leverage synergies between its two business segments. Its scale allows it to negotiate favorable terms with suppliers and to invest in large scale clinical trials. These factors help Johnson & Johnson maintain stable market share and generate consistent cash flow.

The company sells its products to a broad range of customers including hospitals health systems retail pharmacies wholesalers distributors and independent clinicians. In the Innovative Medicine segment medicines are supplied directly to retailers wholesalers distributors hospitals and healthcare professionals for prescription use. In the MedTech segment devices are sold to wholesalers hospitals retailers and are used by physicians nurses eye care professionals and clinics. Vision products are specifically marketed to eye care professionals and ophthalmic surgeons. Overall the customer base is diversified across acute care settings outpatient clinics and retail channels.